Abstract
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) is a C-type lectin receptor expressed on antigen-presenting cells, crucial for pathogen recognition and immune modulation. The shallow and polar carbohydrate binding site of DC-SIGN presents challenges for ligand design. Here, we explored covalent modification targeting specific lysine residues as a novel strategy to modulate DC-SIGN function. Screening a lysine-targeted electrophilic fragment library using orthogonal functional assays identified two potent activators. Structural analyses via NMR spectroscopy, mass spectrometry and computational modeling confirmed structural perturbations of the carbohydrate recognition domain and revealed distinct mechanisms of activation. While both activators significantly enhanced DC-SIGN’s affinity for monosaccharide ligands, one compound induced oligomerization via covalent coupling and non-covalent secondary site interactions, whereas the other selectively modified lysine K373 directly within the primary carbohydrate-binding site. These findings demonstrate the potential of lysine-targeted covalent compounds as a novel therapeutic strategy for modulating DC-SIGN function and potentially C-type lectins in general. Table of contents We introduce the first covalent activators of a C-type lectin. Using GCI, NMR, MS/MS and computational modeling, we delineate mechanisms from a functional electrophile-first screen on DC-SIGN that yields two modes: NHS-ester 11 modifies K379 to induce CRD oligomerization via a secondary site, and squarate 33 modifies K373 in the carbohydrate site to strengthen glycan binding.
Full text
1,826 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) is a C-type lectin receptor expressed on antigen-presenting cells, crucial for pathogen recognition and immune modulation. The shallow and polar carbohydrate binding site of DC-SIGN presents challenges for ligand design. Here, we explored covalent modification targeting specific lysine residues as a novel strategy to modulate DC-SIGN function. Screening a lysine-targeted electrophilic fragment library using orthogonal functional assays identified two potent activators. Structural analyses via NMR spectroscopy, mass spectrometry and computational modeling confirmed structural perturbations of the carbohydrate recognition domain and revealed distinct mechanisms of activation. While both activators significantly enhanced DC-SIGN’s affinity for monosaccharide ligands, one compound induced oligomerization via covalent coupling and non-covalent secondary site interactions, whereas the other selectively modified lysine K373 directly within the primary carbohydrate-binding site. These findings demonstrate the potential of lysine-targeted covalent compounds as a novel therapeutic strategy for modulating DC-SIGN function and potentially C-type lectins in general.
Table of contentsWe introduce the first covalent activators of a C-type lectin. Using GCI, NMR, MS/MS and computational modeling, we delineate mechanisms from a functional electrophile-first screen on DC-SIGN that yields two modes: NHS-ester 11 modifies K379 to induce CRD oligomerization via a secondary site, and squarate 33 modifies K373 in the carbohydrate site to strengthen glycan binding.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
↵* Email: Christoph.Rademacher{at}univie.ac.at, keseru.gyorgy{at}ttk.hu
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.